Analysts Set Expectations for NAMS Q1 Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of NewAmsterdam Pharma in a research note issued on Thursday, February 19th. HC Wainwright analyst L. Egana-Gorrono expects that the company will earn ($0.35) per share for the quarter. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q2 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.35) EPS, FY2026 earnings at ($1.62) EPS, FY2027 earnings at $2.36 EPS, FY2028 earnings at $3.83 EPS, FY2029 earnings at $7.02 EPS and FY2030 earnings at $7.87 EPS.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%.

Other research analysts have also recently issued reports about the stock. Needham & Company LLC lifted their price objective on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Royal Bank Of Canada lifted their price target on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. The Goldman Sachs Group boosted their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Finally, Leerink Partners reissued an “outperform” rating and set a $55.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $47.00.

NewAmsterdam Pharma Stock Up 1.7%

NAMS stock opened at $36.17 on Monday. The company’s 50-day moving average price is $33.98 and its two-hundred day moving average price is $32.78. The firm has a market cap of $4.10 billion, a P/E ratio of -20.91 and a beta of 0.06. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $42.00.

Insider Activity at NewAmsterdam Pharma

In related news, insider Johannes Jacob Piete Kastelein sold 6,000 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $33.25, for a total value of $199,500.00. Following the transaction, the insider owned 73,481 shares in the company, valued at $2,443,243.25. The trade was a 7.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Louise Frederika Kooij sold 32,612 shares of the stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $31.80, for a total value of $1,037,061.60. Following the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at approximately $774,425.40. The trade was a 57.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 298,647 shares of company stock worth $10,236,050 over the last quarter. 20.84% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC increased its holdings in NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after purchasing an additional 708 shares in the last quarter. Mather Group LLC. acquired a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at $30,000. Wells Fargo & Company MN increased its stake in shares of NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after acquiring an additional 300 shares in the last quarter. Finally, Navalign LLC acquired a new position in shares of NewAmsterdam Pharma during the 4th quarter valued at $46,000. 89.89% of the stock is owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.